MIRA

Handel nachbörslich: 1.09 0.03 +2.83%

Mira Pharmaceuticals Inc (MIRA)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Mira Pharmaceuticals Inc

Healthcare (1176)

813-369-5150

1200 BRICKELL AVENUE, MIAMI

Nächster Verdiensttermin

Neueste SEC-Einreichungen

MIRA's Discussions on Twitter

Vergleichen Sie MIRA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MIRA Mira Pharmaceuticals Inc	1.06	17.55M	0	-12.78M	-4.71M	-0.8815
LLY Lilly Eli Co	767.76	690.46B	40.86B	8.37B	-2.28B	9.25
NVO Novo Nordisk Adr	85.00	377.54B	39.36B	13.79B	9.83B	3.086
JNJ Johnson Johnson	144.47	347.83B	87.70B	14.68B	19.03B	6.05
ABBV Abbvie Inc	175.58	310.27B	55.53B	5.12B	15.62B	2.88
MRK Merck Co Inc	98.05	248.03B	63.17B	12.15B	14.84B	4.77

Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten

Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)

Mira Pharmaceuticals Inc (MIRA)

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Vergleichen Sie MIRA mit anderen Aktien

Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten

MIRA Pharmaceuticals Submits IND for Ketamir-2, Targeting Unmet Needs in Neuropathic Pain Treatment - Barchart

Grain Spreads: Profit Taking Theme - Barchart

Stocks Rally On Dovish PCE Inflation Report - Barchart

Gilead Stock Gains 15.4% In A Year: Should You Buy, Sell Or Hold? - Barchart

Is Alexandria Real Estate Stock Underperforming The Nasdaq? - Barchart

Is W.R. Berkley Stock Outperforming The Dow? - Barchart

PayPal Rises 40% In A Year: To Buy Or Not To Buy The PYPL Stock? - Barchart

Arabica Coffee Recovers On Weaker Dollar And Smaller Brazilian Crop - Barchart

Medtronic Stock Declines 5.6% In A Month: Time To Buy The Dip? - Barchart

Stocks Regain Footing On Dovish PCE Inflation Report - Barchart

Enterprise Products Stock Rises 25% YTD: Should You Buy Now Or Avoid It? - Barchart

Knightscope K7 Alpha Testing Underway And 2024 Recap - Barchart

Take-Two (NASDAQ:TTWO): Strongest Q3 Results From The Video Gaming Group - Barchart

Stocks Pare Losses on Dovish PCE Report, But Threats Remain from Triple-Witching and Government Shutdown - Barchart

Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks - Barchart

Rude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart

Crude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart

C3.ai Stock: Buy, Sell, Or Steer Clear? - Barchart

Federal Reserve's Preferred Inflation Gauge Shows Price Pressures Eased Last Month - Barchart

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire

MIRA Pharmaceuticals Submits FDA Application for Breakthrough Pain Treatment Targeting $3.1B Market - StockTitan

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment - Benzinga

AI’s Next Big Winners: 3 Small-Cap Stocks To Watch In 2025 - Barchart

1 'Strong Buy' Penny Stock With 259% Upside Potential - Barchart

4 Big Drug Stocks That May Continue To Outperform In 2025 - Barchart

Will SentinelOne Stock Break Out In 2025? - Barchart

Should You Buy Bitcoin Below $115,000? - Barchart

Should You Buy Palantir Before Dec. 23? - Barchart

Meet the Dow Jones' Top Performing Stock This Year. It's Climbed 2,300% Over the Past 5 Years, and Its Biggest Catalyst May Be Just Ahead. - Barchart

Wall Street's 3 Favorite Auto Stocks Worth Buying For 2025 - Barchart

This AI Stock Could Get Supercharged In 2025 Thanks To Apple - Barchart

Below-Average Rainfall In Brazil Supports Coffee Prices - Barchart

Is Super Micro Stock A Buy, Sell, Or Hold Amidst Nasdaq Troubles? - Barchart

MIRA Pharmaceuticals (NASDAQ:MIRA) Validates Ketamir-2’s Safety Profile with No Adverse Findings, Paving the Way for IND Submission by Year-End - Defense World

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Brazosport Facts

MIRA Pharmaceuticals' Novel Ketamine Drug Aces Preclinical Safety Tests, Phase I Trials Set for 2025 - StockTitan

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain - Yahoo Finance

Stocks Settle Lower Ahead Of US Inflation News - Barchart

Marvell Technology (NASDAQ:MRVL) Delivers Strong Q3 Numbers, Stock Soars - Barchart

Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart

A Look Back at Large-format Grocery & General Merchandise Retailer Stocks’ Q3 Earnings: Walmart (NYSE:WMT) Vs The Rest Of The Pack - Barchart

1 Standout Stock To Buy At A Discount After Strong Earnings - Barchart

Walmart becomes the latestand biggestcompany to pull back back on diversity, equity and inclusion initiatives - Barchart

NVDA Stock Looks Cheap To Value Buyers Based On Its Huge FCF Margins - Barchart

Stocks Rally On The Prospects Of Trump’s Business-Friendly Policies - Barchart

Mira Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia

Mira Pharmaceuticals appoints new board member - Investing.com India

MIRA Pharmaceuticals Appoints New Board Member and Chairman - TipRanks

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - AccessWire

Buy Nvidia's Stock For Another Leg Higher As Q3 Earnings Approach? - Barchart

2 Cybersecurity Stocks To Buy And Hold For 2025 - Barchart

Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie MIRA